IP Library Granted Patent US 8,748,604
Granted Patent B2
US 8,748,604 · App. 13/582,513 · Granted Jun 10, 2014

Process for stereoselective synthesis of 5-fluoro-1-(2R,5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

Inventors: Prakash Bhimaji Kshirsagar (Pune, IN); Satish Manohar Bhoge (Ahmednagar, IN); Santosh Richhariya (Sagar, IN); Kaptan Singh (Ghaziabad, IN)
Assignee: Ranbaxy Laboratories Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,748,604
App. No.
13/582,513
Granted
Jun 10, 2014
Kind
B2
Abstract

The present invention provides an improved process for stereoselective preparation of 5-fluoro-1-(2R,5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine and pharmaceutically acceptable salts thereof.

Claims (34)

1. A process for the preparation of emtricitabine of Formula I,

comprising the steps of:

a) salifying compound of Formula II;

b) reducing the salt obtained in step (a) in the presence of a phosphate buffer;

c) isolating emtricitabine as salt;

wherein, ‘X’ is anion of an acid,

d) recovering emtricitabine as free base using tri-n-butylamine.

2. The process according to claim 1 , wherein the compound of Formula II is salified using an organic or inorganic acid.

3. The process according to claim 1 , wherein reduction is carried out using a reducing agent selected from a group consisting of metal hydride reagents or boranes.

4. The process according to claim 1 , wherein emtricitabine is isolated as an organic or inorganic acid salt.

5. A process for the preparation of emtricitabine of Formula I,

comprising the steps of:

a) reacting 5-fluorocytosine derivative of Formula IV,

wherein ‘P’ is hydrogen or protecting group,

with a 1,3-oxathiolane derivative of Formula V,

wherein ‘L’ is a leaving group,

to give a compound of Formula II,

b) salifying the compound of Formula II;

c) reducing the salt obtained in step (b) in the presence of a phosphate buffer;

d) isolating emtricitabine as its salt;

wherein, ‘X’ is anion of an acid,

e) recovering emtricitabine free base, using tri-n-butylamine.

6. The process according to claim 5 , wherein ‘P’ is an alkyl silyl group.

7. The process according to claim 5 , wherein ‘P’ is a trimethyl silyl group.

8. The process according to claim 5 , wherein ‘L’ is a leaving group selected from a group consisting of halogens.

9. The process according to claim 8 , wherein ‘L’ is chlorine.

10. The process according to claim 5 , wherein the compound of Formula II is salified using an organic or inorganic acid.

11. The process according to claim 10 , wherein an organic acid is selected from a group consisting of acetic acid, lactic acid, salicylic acid, citric acid, tartraric acid, bitartraric acid, ascorbic acid, oxalic acid, succinic acid, maleic acid, fumaric acid, benzoic acid, glutamic acid, methanesulfonic acid, ethanesulfonic acid, benzensulfonic acid or p-toluenesulfonic acid.

12. The process according to claim 11 , wherein an organic acid is oxalic acid.

13. The process according to claim 5 , wherein reduction is carried out using a reducing agent selected from a group consisting of metal hydride reagents or boranes.

14. The process according to claim 13 , wherein reduction is carried out using metal hydride.

15. The process according to claim 14 , wherein reduction is carried out using sodium borohydride.

16. The process according to claim 5 , wherein emtricitabine is isolated as an organic or inorganic acid salt.

17. The process according to claim 16 , wherein emtricitabine is isolated as a hydrochloride.

Assignments (2)
MERGER Recorded Jan 13, 2016
From: RANBAXY LABORATORIES LIMTED
To: SUN PHARMACEUTICAL INDUSTRIES LIMITED
Reel/Frame 037513/0475 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2012
From: KSHIRSAGAR, PRAKASH BHIMAJI; BHOGE, SATISH MANOHAR; RICHHARIYA, SANTOSH; SINGH, KAPTAN
To: RANBAXY LABORATORIES LIMITED
Reel/Frame 028957/0343 →
Priority Claims (1)
IN 489/DEL/2010 · Mar 4, 2010 · national
Continuity (1)
Related Publication 20130072681A1 · Mar 21, 2013